Efficacy and Safety of Combination Therapy With Everolimus and Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation

被引:48
作者
De Simone, P. [1 ]
Crocetti, L. [2 ]
Pezzati, D. [1 ]
Bargellini, I. [2 ]
Ghinolfi, D. [1 ]
Carrai, P. [1 ]
Leonardi, G. [1 ]
Della Pina, C. [2 ]
Cioni, D. [2 ]
Pollina, L. [3 ]
Campani, D. [3 ]
Bartolozzi, C. [2 ]
Lencioni, R. [2 ]
Filipponi, F. [1 ]
机构
[1] Univ Pisa, Med Sch Hosp, Hepatobiliary Surg & Liver Transplantat Unit, I-56124 Pisa, Italy
[2] Univ Pisa, Med Sch Hosp, Dept Radiol, I-56124 Pisa, Italy
[3] Univ Pisa, Med Sch Hosp, Dept Pathol, I-56124 Pisa, Italy
关键词
MANAGEMENT;
D O I
10.1016/j.transproceed.2013.10.035
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is still associated with a dismal outcome. Combination therapy with everolimus (EVL) and vascular endothelial growth factor inhibitor sorafenib (SORA) is based on the role of both b-Raf and mammalian target of rapamycin/protein kinase B pathways in the pathogenesis of HCC and is being investigated in clinical practice. Methods. This was a single-center retrospective analysis on LT recipients with unresectable HCC recurrence and undergoing combination therapy with EVL and SORA. Patients were included if they were switched to EVL+SORA at any time after surgery. Primary endpoint was overall survival (OS) after both LT and recurrence, and response to treatment based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) in the intention-to-treat (ITT) population. Secondary analysis was safety of combination therapy with EVL and SORA in the population of patients who received >= 1 dose of the study drug. Results. Seven patients (100% male; median age 53 years [interguartile range (IQR) 9 years]) were considered for analysis. HCC recurrence was diagnosed at a median (IQR) interval since LT of 9 (126) months, and patients were administered EVL+SORA at a median interval since LT of 11 (126) months. Baseline immunosuppression was with tacrolimus (TAC) in 2 patients (28.6%), cyclosporine (CsA) in 2 (28.6%), and EVL monotherapy in 3 (42.8%). At a median (IQR) follow-up of 6.5 (14) months, 5 patients (71.4%) were alive, 4 of them (57.1%) with tumor progression according to the mRECIST criteria. Median (IQR) time to progression was 3.5 (12) months. Two patients died at a median (IQR) follow-up of 5 (1) months owing to tumor progression in 1 patient (14.3%) and sepsis in the other (14.3%). EVL monotherapy was achieved in 6 patients (85.7%), whereas 1patient (14.3%) could not withdraw from calcineurin inhibitor owing to acute rejection. Treatment complications were: hand-foot syndrome in 5 patients (71.4%), hypertension in 1 (14.3%), alopecia in 1 (14.3%), hypothyroidism in 1 (14.3%), diarrhea in 2 (28.6%), pruritus in 1 (14.3%), abdominal pain in 1 (14.3%), rash in 1 (14.3%), asthenia in 3 (42.8%), anorexia in 3 (42.8%), and hoarseness in 2 (28.6%). Adverse events led to temporary SORA discontinuation in 2 patients (28.6%) and to SORA dose reduction in 3 (42.8%). Conclusions. Treatment of HCC recurrence after LT with a combination regimen of EVL+ SORA is challenging because of SORA-related complications. Longer follow-up periods and larger series are needed to better capture the impact of such combination treatment on tumor progression and patient survival.
引用
收藏
页码:241 / 244
页数:4
相关论文
共 10 条
[1]  
[Anonymous], 2012, LIVER TRANSPLANT, V18, P1154, DOI DOI 10.1002/LT.23481
[2]   Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle [J].
Bhoori, Sherrie ;
Toffanin, Sara ;
Sposito, Carlo ;
Germini, Alessandro ;
Pellegrinelli, Alessandro ;
Lampis, Andrea ;
Mazzaferro, Vincenzo .
JOURNAL OF HEPATOLOGY, 2010, 52 (05) :771-775
[3]   Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation [J].
Frenette, Catherine T. ;
Boktour, Maha ;
Burroughs, Sherilyn G. ;
Kaseb, Ahmed ;
Aloia, Thomas A. ;
Galati, Joseph ;
Gaber, Ahmed O. ;
Monsour, Howard, Jr. ;
Ghobrial, Rafik M. .
TRANSPLANT INTERNATIONAL, 2013, 26 (07) :734-739
[4]   Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation [J].
Gomez-Martin, Carlos ;
Bustamante, Javier ;
Castroagudin, Javier F. ;
Salcedo, Magdalena ;
Garralda, Elena ;
Testillano, Milagros ;
Herrero, Ignacio ;
Matilla, Ana ;
Sangro, Bruno .
LIVER TRANSPLANTATION, 2012, 18 (01) :45-52
[5]  
Jia N, 2013, ANTICANCER RES, V33, P2797
[6]   Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma [J].
Lencioni, Riccardo ;
Llovet, Josep M. .
SEMINARS IN LIVER DISEASE, 2010, 30 (01) :52-60
[7]   Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma [J].
Rodriguez-Peralvarez, Manuel ;
Tsochatzis, Emmanuel ;
Carmen Naveas, Maria ;
Pieri, Giulia ;
Garcia-Caparros, Carmen ;
O'Beirne, James ;
Poyato-Gonzalez, Antonio ;
Ferrin-Sanchez, Gustavo ;
Luis Montero-Alvarez, Jose ;
Patch, David ;
Thorburn, Douglas ;
Briceno, Javier ;
De la Mata, Manuel ;
Burroughs, Andrew Kenneth .
JOURNAL OF HEPATOLOGY, 2013, 59 (06) :1193-1199
[8]   Management of Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients: A Systematic Review [J].
Rubin, Joshua ;
Ayoub, Noel ;
Kaldas, Fady ;
Saab, Sammy .
EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2012, 10 (06) :531-543
[9]   Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study [J].
Sposito, Carlo ;
Mariani, Luigi ;
Germini, Alessandro ;
Reyes, Maria Flores ;
Bongini, Marco ;
Grossi, Glenda ;
Bhoori, Sherrie ;
Mazzaferro, Vincenzo .
JOURNAL OF HEPATOLOGY, 2013, 59 (01) :59-66
[10]   Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature [J].
Zavaglia, Claudio ;
Airoldi, Aldo ;
Mancuso, Andrea ;
Vangeli, Marcello ;
Vigano, Raffaella ;
Cordone, Gabriella ;
Gentiluomo, Maria ;
Belli, Luca Saverio .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (02) :180-186